<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/72CE4418-63D4-4E91-B50A-C3051082309F"><gtr:id>72CE4418-63D4-4E91-B50A-C3051082309F</gtr:id><gtr:name>Hospital La Fe</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/103D3F37-4066-444D-93DA-A10CF99F10F5"><gtr:id>103D3F37-4066-444D-93DA-A10CF99F10F5</gtr:id><gtr:name>Austrian Academy of Sciences</gtr:name><gtr:address><gtr:line1>Lazarettgasse 14</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4A4090D5-D795-4C4B-8A6B-00D25830130F"><gtr:id>4A4090D5-D795-4C4B-8A6B-00D25830130F</gtr:id><gtr:name>University of Duisburg-Essen</gtr:name><gtr:address><gtr:line1>University of Duisburg-Essen</gtr:line1><gtr:line2>Geibelstrase 41</gtr:line2><gtr:line4>Duisburg</gtr:line4><gtr:line5>D-47057</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Immunity and Infection</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/72CE4418-63D4-4E91-B50A-C3051082309F"><gtr:id>72CE4418-63D4-4E91-B50A-C3051082309F</gtr:id><gtr:name>Hospital La Fe</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/103D3F37-4066-444D-93DA-A10CF99F10F5"><gtr:id>103D3F37-4066-444D-93DA-A10CF99F10F5</gtr:id><gtr:name>Austrian Academy of Sciences</gtr:name><gtr:address><gtr:line1>Lazarettgasse 14</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A4090D5-D795-4C4B-8A6B-00D25830130F"><gtr:id>4A4090D5-D795-4C4B-8A6B-00D25830130F</gtr:id><gtr:name>University of Duisburg-Essen</gtr:name><gtr:address><gtr:line1>University of Duisburg-Essen</gtr:line1><gtr:line2>Geibelstrase 41</gtr:line2><gtr:line4>Duisburg</gtr:line4><gtr:line5>D-47057</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F099DF08-DA32-4171-BBEC-25F3EB9D99A7"><gtr:id>F099DF08-DA32-4171-BBEC-25F3EB9D99A7</gtr:id><gtr:firstName>Paloma</gtr:firstName><gtr:surname>Garcia</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FK01076X%2F1"><gtr:id>9C892327-2281-48C3-B85D-E8CFA4AE0B16</gtr:id><gtr:title>The role of MYBL2 in the age-related development of blood disorders</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K01076X/1</gtr:grantReference><gtr:abstractText>Our ability to maintain a supply of healthy functional blood cells throughout our lives is absolutely dependent on the presence in our bone marrow of specialized stem cells. Like other stem cells in the body, these blood stem cells serve to provide a supply of mature cells as required and at the same time are able to make copies of themselves so that they do not become depleted throughout life. As we age, the blood stem cells can gradually acquire mutations in their genetic material sometimes leading to the appearance either of blood disorders in which either the normal number of type of blood cells produced is disrupted or a leukaemia arises. A protein that we know to be critical to limit genetic damage as cells divide is known as MYBL2, and loss of the gene coding for this appears to be linked to certain age-related blood disorders and leukaemia. I have generated a mouse model mimicking the way in which MYBL2 is altered in some patients with blood disorders and I wish to use this to study the precise way in which changes in this protein in stem cells can cause blood diseases as we get older. The outcomes of the project should provide new information to aid diagnosis and prognosis, and may lead to novel treatments for leukaemia and age-related decline in stem cell function.</gtr:abstractText><gtr:technicalSummary>The haemopoietic system is prone to age-related disorders ranging from deficits in functional blood cells to the development of a variety of neoplastic states. Haemopoietic neoplasms often involve defining cytogenetic abnormalities, frequent amongst which is a deletion in the long arm of chromosome 20 (del20q). MYBL2, a key protein involved in the maintenance of genome integrity, is encoded within the minimum del20q region, suggesting a causative role for the factor in disease onset or progression. 

I have demonstrated that mice expressing half the normal level of MYBL2 are susceptible to the development of myeloid disorders with age. Moreover, analysis of global expression studies conducted with cells from patients with myelodysplastic syndrome (MDS) confirmed that down regulation of MYBL2 expression levels correlates with poor prognosis (in refractory anaemia with excess blasts (RAEB)), regardless of the cytogenetic abnormality. The importance of MYBL2 in myeloid neoplasms is supported by a strong correlation between MYBL2 RNA levels and expression of a subset of genes related to cell cycle checkpoint control in cells from patients with MDS. 

This project will utilize the mouse model of MYBL2 haploinsufficiency as a tool to study the molecular mechanisms of initiation and progression of haematological malignancies during ageing. The project will also investigate the molecular mechanisms leading to down-regulation of MYBL2 observed in MDS patients that do not exhibit del20q. 

If it can be validated that down-regulation of MYBL2 is related to MDS with bad prognosis, then MYBL2 could potentially serve as prognostic biomarker of disease progression and have an impact in prospective therapeutic strategies for MDS patients.</gtr:technicalSummary><gtr:potentialImpactText>Impact on Knowledge - New information on the the molecular mechanisms that govern blood disorders during ageing will be generated by this project. This will be disseminated through publication in international journals and as well through channels such as the annual Molecular Haematology meeting (held in London), stem cell centre, BUSCC, and the regional stem cell network, MSCA.

Impact on Communication and Engagement - This will be achieved through the auspices of BUSCC and as part of the University of Birmingham Heroes campaign. Events will be held locally in the University or the city of Birmingham at which the public can engage in informed debate about a variety of issues related to stem cell science.

Impact on health and quality of life - The research in this project will not be only fundamental research, but will also study blood disorders using human samples. There will be opportunities to communicate the output to the local clinical haematology community as a part of this type of collaborative projects that are more translational. Long-term, the findings from this project should impact on health issues ranging from prognosis, the treatment of MDS and alleviation of age-related declines in stem cell function.

Impact on International Collaboration - This project will help to mantain an already established international collaboration with the group of Robert Kralovics in Vienna.

Impact on People - The project will lead to training of a postdoctoral staff, and will impact on the training of others in the laboratory, including PhD students, undergraduate students and master students. The expertise of the principal applicant and collaborators, and the new knowledge gained will be of use to several other research groups in the local research environment, as well as the wider community in Birmingham. 
 
Impact on the Economy - We will continue to contribute to development of the local science infrastructure and in providing skilled researchers needed for academia and industry, and this is of particular relevance given the Science City status held by Birmingham and what this means in terms of linking academic output to local industries.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-10-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-06-03</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>430925</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Austrian Academy of Sciences</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:department>Research Centre for Molecular Medicine (CeMM)</gtr:department><gtr:description>MYBL2 in MDS</gtr:description><gtr:id>662A623F-1641-4EE1-9D79-9563491DCDD8</gtr:id><gtr:impact>PMID22910183</gtr:impact><gtr:partnerContribution>Acces to data and equipment as well as intellectual input</gtr:partnerContribution><gtr:piContribution>Genetically modified mice: B-Myb conditional KO mouse</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Duisburg-Essen</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>MYBL2 in MDS using B-myb mouse model</gtr:description><gtr:id>FE2B8C44-81EA-4BA3-ABB5-64F9DE581DA4</gtr:id><gtr:impact>Collaboration just started (November 2015, MTA agreement completed in January 2016).</gtr:impact><gtr:partnerContribution>Sharing experiment and knowledge</gtr:partnerContribution><gtr:piContribution>An MTA agreement has been established so the group of Dr Stefan Heinrichs can use our Bmyb mouse models to study cooperative mutations in the development of MDS.
(sharing material)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hospital La Fe</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>MYBL2 in AML</gtr:description><gtr:id>C6E8C401-B19B-4737-947F-22226C153248</gtr:id><gtr:impact>http://dx.doi.org/10.1016/j.leukres.2013.09.015</gtr:impact><gtr:partnerContribution>Intellectual input, access to data
http://dx.doi.org/10.1016/j.leukres.2013.09.015</gtr:partnerContribution><gtr:piContribution>Intellectual Input, hosting PhD students</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Cancer Sciences Birmingham</gtr:department><gtr:description>genome stability DNA damage studies</gtr:description><gtr:id>E9EC52CC-464F-470D-8DE8-0A9C0EC054F6</gtr:id><gtr:impact>PMID22945645</gtr:impact><gtr:partnerContribution>Intellectual input and access to equipment and material</gtr:partnerContribution><gtr:piContribution>Intelectual input and access to equipment and material</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Bloodwise Grant Holder day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4421C090-5A53-4FD5-BEC0-42F982F277C0</gtr:id><gtr:impact>Grant Holder day for Bloodwise in which there were not only presentations but as well the possibility to talk to director of the funding body who gave an explanation of the bankruptcy suffered by the charity and the plans for the future.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Shadowing undergraduate studnets</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A136463A-EA95-4A1E-87BC-FF4DF37DBFE2</gtr:id><gtr:impact>2 undergraduate medical students attended my lab during one week, they saw how research is conducted and questioned about our research , as a consequence of this one of the students is planning to intercalate next year.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Molecular hameatology meeting Lonon</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3FC2BF0D-C991-4269-B29F-C1DBDEDB423F</gtr:id><gtr:impact>Moleculal hematology meeting to interact and network with other groups within the field. Aside of the talks, the coffee breaks and lunch were really important for engaging with other groups and discus about our work.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Poster IPSc and reprogramming in Copenhagen conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7F2E47BA-4127-4A03-86F7-1315AB075F9C</gtr:id><gtr:impact>Congress in Copenhagen organized by DanStem.
I presented a poster related to our work on reprogramming, but the congress of around 150 scientists was broader than reprogramming, and had the opportunity to discuss my work related to iPSC as well as haematopoietic stem cells and genomics with renown scientists such as Richard Young, Emmanuelle Passague, Valentina Greco, Veronique Azuara etc.
the meeting was really well organized with many events aim to mix people and to maximize interaction.
I was also chosen to be one of the judges for best postdoctoral researcher poster .
It alos gave me the opportunity to meet with my collaborator Keisuke Kaji.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://danstem.ku.dk/the-stem-cell-niche-2016/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Birmingham cancer showcase</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>AACC5085-CA48-44D6-872A-3D199FCAE6ED</gtr:id><gtr:impact>The labs were opened for people to come and visit and ask questions about our research in cancer and blood disorders. 
We organized ourselves in different teams to explain them our research, the importnce, what we wanted to achieve and let them do &amp;quot;experiments&amp;quot; such as DNA extraction from strwberries or looking blood samples through the microscope etc.

Members of the public and patients with blood disorders were pleased with what they saw, made questions and enjoyed their visits.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.birmingham.ac.uk/university/colleges/mds/events/2015/06/BirminghamCancerShowcase.aspx</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Paloma Shadowing</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8834A95F-8898-4FD8-AEEE-6FEF14464485</gtr:id><gtr:impact>Shadowing a 17 year old student and 2 undergraduate students from Brazil during summer. 

Lots of discussion, questions and interest.



They just really loved to be in a lab, in fact the 7 years old did not want to come back to school, wanted to start unievrsity and become a sceintist straight away.

The 2 undergraduates students have decided to follow a career in Science and are finishing their degrees in order to do so.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Genome Stability Network meeting, Cambridge</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3B55E509-256D-4761-87CB-4BBD2379214D</gtr:id><gtr:impact>Genome stability network meeting, held in Cambridge.
The audience engaged with were team leaders, postdoctoral reearchers and PhD students working in the field.
We also counted with memebers of Industry such as Astra Zeneca and Nobel Prize 2015 Tomas Lindhal.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:url>http://genomestabilitynetwork.org.uk/UK_GSN/Meetings_files/GSN_prog_2016.pdf</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open day Cancer Research</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>78E997F3-1D0E-4781-BC50-9B2C52F2AD58</gtr:id><gtr:impact>General aundience interested on teh Research conducted at teh University of Birmingham, specifically related to leukaemias. some of them were patients that have pre-leukaemiac conditions and were treated on the QE hospital.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Astra Zeneca</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8A8ECD53-9751-4D4C-88AB-B6D18FFAD231</gtr:id><gtr:impact>Talk to Astra Zeneca about our reserach to look for common points and possible collaboratio</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laila Shadowing</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7E1F10AF-BC62-4F90-9475-061E72A68652</gtr:id><gtr:impact>3 pupils fro primary school visiting for career decision

students understood what career in research would be.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>patients with MDS/AMl visiting the lab</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>83620418-A229-49C6-8DEC-E786F6618BF2</gtr:id><gtr:impact>3 patients suffering with blood disorders visited the lab and were explained our research and showed the different equipment we had in the lab to carry on the research. They seemed quite interested and impressed with the type of research we were doing.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC proximity to Discovery</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>University of Birmingham</gtr:fundingOrg><gtr:id>2D4173D6-41E0-436A-AE5B-5FE7D51A4E74</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>80000</gtr:amountPounds><gtr:country>Saudi Arabia, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Saudi Government studentship</gtr:description><gtr:end>2021-04-02</gtr:end><gtr:fundingOrg>Government of Saudi Arabia</gtr:fundingOrg><gtr:id>5EC59165-A09C-43F2-B109-44564D9F2642</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4937</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Preliminary data Award</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>University of Birmingham</gtr:fundingOrg><gtr:id>04C9678B-521A-4F31-9DA3-1298C3E17911</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Program grant LLR</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>76C6DBEF-37E0-427F-8EEB-15833842DAD3</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Setting up fixation conditions to use double immunfluorescence staining for the same sample to reduce number of animals per experiment to half.</gtr:description><gtr:id>6A05BEE1-DC95-4327-BA1C-79BAE11CE11A</gtr:id><gtr:impact>Reduce number of animals to half by being able to study two proteins at the same time in the same biological sample</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>immunofluorescences</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/11C999DF-A6AB-4DEC-BF45-D92339D18E07"><gtr:id>11C999DF-A6AB-4DEC-BF45-D92339D18E07</gtr:id><gtr:title>Determining c-Myb protein levels can isolate functional hematopoietic stem cell subtypes.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/06c945536ca15b161e63087b1a915680"><gtr:id>06c945536ca15b161e63087b1a915680</gtr:id><gtr:otherNames>Sakamoto H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/94B897D7-8BDA-4B42-8A26-063F5E58DA89"><gtr:id>94B897D7-8BDA-4B42-8A26-063F5E58DA89</gtr:id><gtr:title>C/EBPa and MYB regulate FLT3 expression in AML.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e2cebd9c1c2830d681ef2ace611d4831"><gtr:id>e2cebd9c1c2830d681ef2ace611d4831</gtr:id><gtr:otherNames>Volpe G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/46AD7BE1-FB4E-4A05-BA09-09E257DE245A"><gtr:id>46AD7BE1-FB4E-4A05-BA09-09E257DE245A</gtr:id><gtr:title>Study of the S427G polymorphism and of MYBL2 variants in patients with acute myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Leukemia &amp; lymphoma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/858057b3968be071119e681df5da1491"><gtr:id>858057b3968be071119e681df5da1491</gtr:id><gtr:otherNames>Dolz S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1026-8022</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7584A87C-3192-4059-87EB-A0A25CD37A56"><gtr:id>7584A87C-3192-4059-87EB-A0A25CD37A56</gtr:id><gtr:title>Adverse prognostic value of MYBL2 overexpression and association with microRNA-30 family in acute myeloid leukemia patients.</gtr:title><gtr:parentPublicationTitle>Leukemia research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/216963934cd20e15b8ec0f492ccc47a8"><gtr:id>216963934cd20e15b8ec0f492ccc47a8</gtr:id><gtr:otherNames>Fuster O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0145-2126</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/88AA3363-EC20-40BD-80D2-334543F38F1E"><gtr:id>88AA3363-EC20-40BD-80D2-334543F38F1E</gtr:id><gtr:title>MYBL2 haploinsufficiency increases susceptibility to age-related haematopoietic neoplasia.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f10f6b8faa715faa1a1670e0712441c4"><gtr:id>f10f6b8faa715faa1a1670e0712441c4</gtr:id><gtr:otherNames>Clarke M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E6862868-02E6-4D05-950B-3C64EF612DBC"><gtr:id>E6862868-02E6-4D05-950B-3C64EF612DBC</gtr:id><gtr:title>Regulation of the Flt3 Gene in Haematopoietic Stem and Early Progenitor Cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e2cebd9c1c2830d681ef2ace611d4831"><gtr:id>e2cebd9c1c2830d681ef2ace611d4831</gtr:id><gtr:otherNames>Volpe G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3EB73F1D-2F78-4521-B18A-8D34DBFE19D4"><gtr:id>3EB73F1D-2F78-4521-B18A-8D34DBFE19D4</gtr:id><gtr:title>Transcriptional regulation of SPROUTY2 by MYB influences myeloid cell proliferation and stem cell properties by enhancing responsiveness to IL-3.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f10f6b8faa715faa1a1670e0712441c4"><gtr:id>f10f6b8faa715faa1a1670e0712441c4</gtr:id><gtr:otherNames>Clarke M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K01076X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>